Webinar Technology

Driving precision medicine through biostatistics: Translating multiomics biomarker data into breakthrough knowledge

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Driving precision medicine through biostatistics: Translating multiomics biomarker data into breakthrough knowledge

03 October 2018

12:00 p.m. ET

Register now!

Speakers

In order to provide better treatment for patients and more effective, targeted drugs, it is vital to understand disease mechanisms and to identify informative markers for patient susceptibility, disease progression, treatment response, and individual drug tolerance. The move to more stratified medicine is a key paradigm for global health care, but also an enormous challenge for biologists and data scientists. Technological developments are enabling larger studies that can rapidly deliver huge quantities of data—their translation into meaningful, actionable biological understanding is essential, but often difficult. Genomics and proteomics are increasingly combined to characterize the role of specific biomarkers in disease, uncover novel biological pathways, provide rationales for drug target selection, and develop new, more efficacious therapies. These large-scale, multiomics studies generate complex datasets that highlight an important example of the big-data problem. At the same time, the credibility of scientific research is facing challenges from the so-called “replication crisis,” raising questions about how we judge the significance of the data we obtain. Thus, biostatisticians play an increasingly critical role in interpreting and quality-assuring the outcome of such studies, throughout the process of biomarker discovery, validation, clinical implementation, and drug development. Our panelists will share their experiences in applying biostatistics to large datasets in order to facilitate more confident development of novel therapeutics, and to drive precision medicine.

During the webinar, the speakers will:

  • Describe their biostatistical approaches to analyzing large, complex datasets
  • Illustrate how biostatistical analysis can translate complex data into biological insights
  • Discuss how biomarkers can be leveraged to identify unique underlying biological mechanisms and personalize patient treatment
  • Answer your questions during the live broadcast!

This webinar will last for approximately 60 minutes.

Speaker bios

Eric Fauman, Ph.D.

Pfizer
Cambridge, MA

Dr. Fauman is a senior scientific director at Pfizer. He received his Ph.D. from the University of California, San Francisco for work on protein structure determination by X-ray crystallography and structure-based drug design. For the past 20 years, he has been a computational biologist at Pfizer, working with disease biologists to identify and prioritize drug targets to address unmet medical needs. He currently leads a team of computational biologists and geneticists dedicated to Computational Target Validation, working across multiple disease areas. Dr. Fauman is particularly interested in the intersection of genetics and quantitative molecular traits, and has published on the analysis and interpretation of molecular and protein quantitative trait loci.

Jasper Tromp, M.D., Ph.D.

University Medical Centre Groningen
Groningen, The Netherlands

Dr. Tromp is a postdoctoral research fellow working jointly at the University of Groningen in the Netherlands and the National Heart Centre Singapore and Duke–NUS Medical School in Singapore. He obtained both his medical degree and Ph.D. from the University of Groningen. As a research fellow, he combines his clinical knowledge as an M.D. with his skills in data analytics and machine learning to identify underlying disease mechanisms in heart failure and to personalize treatment in heart failure patients.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here